TNFRSF17 and Miyoshi myopathy: Chimeric antigen receptor (CAR) T cell therapies targeting B-cell maturation antigen (BCMA) have shown promising responses and outcomes in heavily pretreated and treatment-refractory MM patients, with 48–100% overall response rates and 6–76% complete response rates3–10.